Logo image of CRON.CA

CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis

TSX:CRON - Toronto Stock Exchange - CA22717L1013 - Common Stock - Currency: CAD

2.5  -0.06 (-2.34%)

Fundamental Rating

5

Taking everything into account, CRON scores 5 out of 10 in our fundamental rating. CRON was compared to 34 industry peers in the Pharmaceuticals industry. CRON has a great financial health rating, but its profitability evaluates not so good. CRON is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.
CRON had a positive operating cash flow in the past year.
CRON had negative earnings in 4 of the past 5 years.
In the past 5 years CRON reported 4 times negative operating cash flow.
CRON.CA Yearly Net Income VS EBIT VS OCF VS FCFCRON.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

CRON's Return On Assets of 3.52% is amongst the best of the industry. CRON outperforms 91.18% of its industry peers.
CRON's Return On Equity of 3.86% is amongst the best of the industry. CRON outperforms 88.24% of its industry peers.
Industry RankSector Rank
ROA 3.52%
ROE 3.86%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
CRON.CA Yearly ROA, ROE, ROICCRON.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

CRON's Profit Margin of 34.93% is amongst the best of the industry. CRON outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of CRON has declined.
The Gross Margin of CRON (21.42%) is worse than 70.59% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 34.93%
GM 21.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
CRON.CA Yearly Profit, Operating, Gross MarginsCRON.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

More info and screens

8

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRON has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRON has more shares outstanding
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRON.CA Yearly Shares OutstandingCRON.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CRON.CA Yearly Total Debt VS Total AssetsCRON.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 5.47 indicates that CRON is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.47, CRON belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.47
ROIC/WACCN/A
WACC8.3%
CRON.CA Yearly LT Debt VS Equity VS FCFCRON.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

CRON has a Current Ratio of 18.84. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON has a Current ratio of 18.84. This is amongst the best in the industry. CRON outperforms 100.00% of its industry peers.
CRON has a Quick Ratio of 18.17. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 18.17, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.84
Quick Ratio 18.17
CRON.CA Yearly Current Assets VS Current LiabilitesCRON.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 190.91% over the past year.
CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
CRON shows a strong growth in Revenue. In the last year, the Revenue has grown by 33.82%.
The Revenue has been growing by 37.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)190.91%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%320%
Revenue 1Y (TTM)33.82%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%26.7%

3.2 Future

CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.
CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.87% yearly.
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue Next Year18.44%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y1.87%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CRON.CA Yearly Revenue VS EstimatesCRON.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON.CA Yearly EPS VS EstimatesCRON.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 17.86, the valuation of CRON can be described as rather expensive.
Based on the Price/Earnings ratio, CRON is valued cheaper than 85.29% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.79, CRON is valued a bit cheaper.
The Forward Price/Earnings Ratio is negative for CRON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 17.86
Fwd PE N/A
CRON.CA Price Earnings VS Forward Price EarningsCRON.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

CRON's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 122.1
EV/EBITDA N/A
CRON.CA Per share dataCRON.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as CRON's earnings are expected to decrease with -39.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRONOS GROUP INC

TSX:CRON (4/25/2025, 7:00:00 PM)

2.5

-0.06 (-2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-08 2025-05-08
Inst Owners13.13%
Inst Owner ChangeN/A
Ins Owners5.48%
Ins Owner ChangeN/A
Market Cap963.52M
Analysts74.55
Price Target3.68 (47.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1006.46%
Min EPS beat(2)296.08%
Max EPS beat(2)1716.84%
EPS beat(4)3
Avg EPS beat(4)340.81%
Min EPS beat(4)-684.31%
Max EPS beat(4)1716.84%
EPS beat(8)5
Avg EPS beat(8)171.4%
EPS beat(12)6
Avg EPS beat(12)82.3%
EPS beat(16)8
Avg EPS beat(16)61.24%
Revenue beat(2)1
Avg Revenue beat(2)-2.63%
Min Revenue beat(2)-14.99%
Max Revenue beat(2)9.73%
Revenue beat(4)3
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)-1.68%
Revenue beat(12)5
Avg Revenue beat(12)-4.39%
Revenue beat(16)7
Avg Revenue beat(16)-4.15%
PT rev (1m)0.47%
PT rev (3m)1.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)100%
EPS NY rev (1m)-44.43%
EPS NY rev (3m)3.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.17%
Revenue NY rev (1m)2.63%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE 17.86
Fwd PE N/A
P/S 5.91
P/FCF 122.1
P/OCF 36.86
P/B 0.65
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)0.14
EY5.6%
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)0.02
FCFY0.82%
OCF(TTM)0.07
OCFY2.71%
SpS0.42
BVpS3.83
TBVpS3.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.52%
ROE 3.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 34.93%
GM 21.42%
FCFM 4.84%
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 140.9%
Cap/Sales 11.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 13.85%
Current Ratio 18.84
Quick Ratio 18.17
Altman-Z 5.47
F-Score6
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190.91%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%320%
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)33.82%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%26.7%
Revenue Next Year18.44%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y1.87%
EBIT growth 1Y26.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.36%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y112.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.99%
OCF growth 3YN/A
OCF growth 5YN/A